DaVita Inc.
0I7E.L
London Stock Exchange226.50
USD
-4.30
- -
DaVita Inc.
0I7E.L
(London Stock Exchange)
Recent
price
226.50
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- DaVita Inc. (NYSE: DVA; LSE: 0I7E) operates as a leading provider of kidney care services in the United States, focusing on integrated dialysis and related health services for patients with chronic kidney failure and end-stage renal disease. The company owns and operates approximately 2,900 outpatient dialysis centers and more than 370 acute inpatient dialysis units, delivering hemodialysis and peritoneal dialysis treatments; it also provides kidney care services, including disease management, vascular access management, clinical research, and transplant services through its DaVita Kidney Care business segment. Additionally, DaVita Integrated Kidney Care offers value-based care arrangements, such as accountable care organizations, physician management services, and disease management programs; the company serves approximately 250,000 patients annually, primarily through partnerships with nephrologists, hospitals, and health systems across the U.S., with limited international operations in countries including Brazil, India, and Saudi Arabia [ from previous][ from previous]. DaVita was founded in 1994 and is headquartered in Denver, Colorado. In recent developments, DaVita announced a strategic collaboration with Amazon Web Services in early 2025 to leverage cloud technology for enhancing patient data analytics and operational efficiency in its dialysis centers. The company completed the acquisition of a portfolio of 32 dialysis clinics from Fresenius Medical Care in mid-2024, expanding its footprint in key U.S. markets; it also launched an expanded portfolio of at-home dialysis solutions under the DaVita Home brand, including next-generation portable hemodialysis machines to support patient mobility and reduce facility dependency. Furthermore, DaVita secured a $500 million financing round in late 2024 led by institutional investors to fund value-based care initiatives and international expansion in Latin America [ from previous]. No significant name changes or reorganizations have occurred in the last two years.